Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference
December 20 2018 - 8:30AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ophthalmology and
rare diseases, today announced the company will be participating in
the upcoming 37th Annual J.P. Morgan Healthcare Conference in San
Francisco, CA.
Adverum’s management is scheduled to present on
Thursday, January 10, 2019 at 8:00am Pacific Time. Interested
parties may access a live and archived webcast of the presentation
on the “Investors” section of the company’s website at:
www.adverum.com. The webcast will be available on the company’s
website for at least two weeks following the event.
About Adverum Biotechnologies,
Inc.Adverum is a clinical-stage gene therapy company
targeting unmet medical needs in ophthalmology and rare diseases.
Adverum develops gene therapy product candidates designed to
provide durable efficacy by inducing sustained expression of a
therapeutic protein. Adverum has collaboration agreements with
Regeneron Pharmaceuticals to research, develop, and commercialize
gene therapy products for ophthalmic diseases and Editas Medicine
to explore the delivery of genome editing medicines for the
treatment of inherited retinal diseases. Adverum’s core
capabilities include clinical development, novel vector discovery
and in-house manufacturing expertise, specifically in scalable
process development, assay development, and current Good
Manufacturing Practices quality control. For more information
please visit www.adverum.com.
Investor and Media Inquiries:
Katherine BockVice President Investor Relations & Corporate
CommunicationsAdverum Biotechnologies,
Inc.650-656-9347kbock@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024